HPV Vaccine Generally Well Tolerated in Men
Human papillomavirus (HPV) vaccines are safe and well tolerated in male patients, with few reports of adverse events.
Human papillomavirus (HPV) vaccines are safe and well tolerated in male patients, with few reports of adverse events.
Three interventions for increased human papillomavirus vaccine coverage are cost-effective.
Clinicians must consider patient sexual history in the decision-making process for adult HPV vaccination.
For women undergoing HPV-based cervical cancer screening, automated evaluation of p16/Ki-67 dual-stained slides reduces the number of colposcopies compared with current standards.
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.
In addition to high antibody levels, factors including exposure to the human papillomavirus (HPV) and antibody avidity may be important and necessary to protect against infection.
Despite reassuring safety data from clinical trials, the adoption of the inactivated HPV vaccine in the United States remains low.
Survey results reveal HPV vaccine delivery practices and experiences among pediatricians and family physicians.
Studies based on searching Vaccine Adverse Event Reporting System, 6 Vaccine Safety Datalink sites.